BIOPHARMA
ByIs Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…
Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital or Closed Data Experiment?
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution or Urban Elite Tool?
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline or Insider Breach Timebomb?
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing AI Leadership in Global Diagnostics—Brainlab Partnership Signals Agentic AI Workflow Revolution
Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040 on 20-25% sustained…
